Express Scripts and FTC Announce Settlement

February 12, 2026

EGWP marketplace medicaid Medicare

On Feb. 4, Express Scripts and the Federal Trade Commission (FTC) announced a comprehensive resolution settlement that addresses concerns raised by the FTC. Details of the global settlement include:

  • As enforced by the settlement, our new, transparent pharmacy benefits model ensures that our patients pay the lowest available cost for their medicines, whether it is our negotiated cost, their copay, or a cash discount price.
  • TrumpRx pricing will be covered for our members so that purchases through TrumpRx will count towards their deductible upon relevant legal and regulatory changes.
    • Express Scripts is the first PBM to partner with TrumpRx, and this would be the first time TrumpRx pricing is available to patients as part of their pharmacy benefits.
  • Ensure Express Scripts’ new industry-leading and transformative price discount (rebate-free) model is widely available to employers and health plan sponsors to lower the cost of all brand medications for their members as our new standard model.
  • Ensure our new reimbursement model based off the pharmacy’s actual acquisition costs is available to retail community pharmacies, and that retail community pharmacies are compensated for other essential clinical services (e.g., certain diagnostic testing and vaccinations).
  • Ensure more lower-priced medicines, including insulins, are covered across all Express Scripts standard formularies – and that our Patient Assurance Program that caps the monthly cost of insulin at $25 is the standard for Express Scripts’ clients.
  • Support the American economy by moving rebate contracting operations conducted on Express Scripts’ behalf to the U.S. 

These are meaningful steps toward making prescription drugs more affordable for millions of families and advancing the goals we share with the administration of full transparency into prescriptions drug costs. This settlement enables us to keep moving forward, and we appreciate the Administration’s reinforcement of our commitment to pharmacy benefits that put Americans first.

Initiatives

Calls grow for Drug Patent reform

In a recent blog post, the Pharmaceutical Care Management Association (PCMA) highlighted increased attention to pharmaceutical companies’ abuse of drug patents. Last month, the Supreme Court unanimously ruled in favor of a generic drugmaker in a “skinny labeling” case, a victory for patients. Skinny labels allow generic and biosimilar competitors to launch products for non-patented indications, helping accelerate […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

perspectives

AHIP calls for Bipartisan reform to address health care cost drivers

On July 23, AHIP President and CEO Mike Tuffin wrote an opinion piece in The New York Times saying, “common-sense bipartisan reforms are needed to promote competition in care delivery and prescription drugs, protect consumers from providers and drugmakers’ anticompetitive practices and transition away from the perverse incentives of fee-for-service medicine.” Tuffin notes that health […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

Solutions

PCMA urges preserving patient access and flexibility in new fertility benefits rule

PCMA recently submitted comments to HHS, DOL, and the Treasury (the Departments) in response to the proposed rule establishing a new category of limited excepted benefits for fertility services. PCMA supports the Departments’ goal of expanding access to fertility care while encouraging employer innovation but urged several targeted refinements to ensure the framework is operationally […]
read more >

August 11, 2026

marketplace medicaid

You may also like